| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Corning's cutting-edge Ascent® Fixed Bed Bioreactor System will be integrated into the institute's renowned training and curriculum programs.
CORNING, N.Y. — Corning Incorporated (NYSE:GLW) today announced a collaboration with the National Institute for Bioprocessing Research and Training (NIBRT), one of the world's premier centers for biopharmaceutical-manufacturing research and training. Under the agreement, NIBRT will host one of Corning's cutting-edge Ascent® Fixed Bed Bioreactor (FBR) Systems at its Advanced Therapies building in Dublin, Ireland.
Corning's Ascent FBR System is an automated bioproduction platform that facilitates the efficient growth and harvesting of large quantities of viable cells, an ongoing challenge for biopharmaceutical manufacturers. It produces high yields of adherent cells, which are used in many areas of modern medicine, including cell therapy, gene therapy, cell-based immuno-oncology, and tissue engineering. The Ascent system has the potential to help shorten the path to clinical applications of cell and gene therapies.
NIBRT will integrate the Ascent system into its customized courses and trainings and provide demonstrations for NIBRT visitors. The collaboration further opens the door for Corning to the life sciences market in Europe, and to the fast-growing Irish market. Ireland is now the third largest exporter of pharmaceuticals in the world.
Posted In: GLW
